Systemic management of malignant meningiomas: A comparative survival and molecular marker analysis between Octreotide in combination with Everolimus and Sunitinib
Fig 2
Overall survival and progression free survival for first-line Everolimus+octreotide and sunitinib (A) Kaplan–Meier curve for first line overall survival (OS).
Everolimus±octreotide and sunitinib offered a median of 36 months (95%CI 25.3–41.7) and 29.5 months (95%CI 22.5–37.5; p = 0.349), respectively. (B) Kaplan–Meier curve for first line progression free survival (PFS). Everolimus±octreotide and sunitinib offered a median of 12.1 months (95%CI 9.2–21.1) and 9.1 months (95%CI 6.8–16.8; p = 0.43), respectively.